Sickle Cell Disease Treatment Market is estimated to be US$ 9.22 billion by 2030 with a CAGR of 15.6% during the forecast period
Sickle Cell
Disease Treatment Market accounted for
US$ 2.20 billion in 2020 and is estimated to be US$ 9.22 billion by 2030
and is anticipated to register a CAGR of 15.6%. Sickle cell disease (SCD) is a group of blood
disorders typically inherited from an individual's parents. The most common
type is understood as red blood cell anemia (SCA). It leads to an abnormality
within the oxygen-carrying protein hemoglobin found in red blood cells. This
results in a rigid, sickle-like shape under certain circumstances. Problems in
red blood cell disease typically begin around 5 to six months aged. Variety of
health problems may develop, like attacks of pain ("sickle cell
crisis"), anemia, swelling within the hands and feet, bacterial infections
and stroke. Long-term pain may develop as people grow old. The typical
anticipation within the developed world is 40 to 60 years. Stem cell or bone
marrow transplants are the only cure for sickle cell disease, but they're not
done very often because of the significant risks involved. Stem cells are
special cells produced by bone marrow, a spongy tissue found in the center of
some bones.
The report “Global Sickle Cell Disease Treatment Market, By
Product (Hematology Analyzers, Flow Cytometers, Coagulation Analyzers, Slide
Stainers, Centrifuges, Hemoglobin meters, Other Products), By Reagents
(Coagulation Reagents, Flow Cytometer Reagents, Immuno-hematology Reagents, and
Other Reagents), By Application (Drug Testing and Auto-Immune Disease), By End
User (Hospitals, Clinical Testing Institutes, Patient Self-testing, and Other
End Users), and By Region (North America, Europe, Asia Pacific, Latin America, and
Middle East & Africa) - Trends, Analysis and Forecast till 2030”
Key Highlights:
·
In 2021,
Bluebird bio, reeling from Zynteglo safety scare, snags EU nod for new gene
therapy against rare neurodegenerative disease.
Analyst View:
The availability of high unmet needs, increasing
product pipeline for treating sickle cell anemia is to create a high demand for
these treatment options. Sickle cell anemia treatment market is driven by
increasing governments and regulatory bodies support using research and
development investment, fast track approval for discovering newer treatments
for this disorder.
Before purchasing this
report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/2230
Key Market Insights from the report:
The Global
Sickle Cell Disease Treatment Market accounted for US$ 2.20 billion in
2020 and is estimated to be US$ 9.22 billion by 2030 and is anticipated to
register a CAGR of 15.6% The global
sickle cell disease treatment market is segmented based on the product,
reagents, application, end-users, and region.
·
By Product,
the Global Sickle Cell Disease Treatment Market is segmented into hematology
analyzers, flow cytometers, coagulation analyzers, slide strainers,
centrifuges, hemoglobin meters, other products.
·
By Reagents,
the Global Sickle Cell Disease Treatment Market is segmented into coagulation
reagents, flow cytometer reagents, immuno-hematology reagents, and other
reagents.
·
By
Application, the Global Sickle Cell Disease Treatment Market is segmented into
drug testing and autoimmune disease.
·
By
End-User, the Global Sickle Cell Disease Treatment Market is segmented into
hospitals, clinical testing institutes, patient self-testing, and other end
users.
·
By region, the
Global Sickle Cell Disease Treatment Market is segmented into North America,
Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in
North America accounts highest revenue share to the global sickle cell disease
treatment market due to the increasing demand for advanced medical technologies
and the rising geriatric population.
Competitive Landscape:
The key players operating the global sickle cell
disease treatment market involves Baxter, Bluebird Bio, Bristol-Myers Squibb
Company, Eli Lilly, Global Blood Therapeutics, Gilead Sciences, Inc., Johnson
& Johnson, Merck & Co., Inc., Mast Therapeutics, Novartis AG, Pfizer,
Inc., and Sanofi.
The market provides detailed information
regarding the industrial base, productivity, strengths, manufacturers, and
recent trends which will help companies enlarge the businesses and promote
financial growth. Furthermore, the report exhibits dynamic factors including
segments, sub-segments, regional marketplaces, competition, dominant key
players, and market forecasts. In addition, the market includes recent
collaborations, mergers, acquisitions, and partnerships along with regulatory
frameworks across different regions impacting the market trajectory. Recent
technological advances and innovations influencing the global market are
included in the report.
About Prophecy Market Insights
Prophecy Market Insights is specialized market
research, analytics, marketing/business strategy, and solutions that offers
strategic and tactical support to clients for making well-informed business
decisions and to identify and achieve high-value opportunities in the target
business area. We also help our clients to address business challenges and
provide the best possible solutions to overcome them and transform their
business.
To know more
Contact Us:
Sales
Prophecy Market Insights
Email- sales@prophecymarketinsights.co
Comments
Post a Comment